Grade 3 or 4 adverse events
| . | All patients . | High-dose dexamethasone patients . | ||||
|---|---|---|---|---|---|---|
| thal/dex (n = 183), n (%) . | len/dex (n = 228), n (%) . | P . | thal/dex (n = 72), n (%) . | len/dex (n = 72), n (%) . | P . | |
| Treatment-related deaths | 1 (0.5) | 3 (1.3) | .632 | 1 (1.4) | 2 (2.8) | > .999 |
| At least one grade 3 or 4 adverse event | 100 (54.6) | 131 (57.5) | .568 | 44 (61.1) | 51 (70.8) | .218 |
| Hematologic | ||||||
| Anemia | 0 (0) | 10 (4.4) | .003 | 0 (0) | 3 (4.2) | .245 |
| Thrombocytopenia | 0 (0) | 11 (4.8) | .002 | 0 (0) | 3 (4.2) | .245 |
| Neutropenia | 1 (0.6) | 32 (14.0) | < .001 | 0 (0) | 10 (13.9) | .001 |
| Extrahematologic | ||||||
| Peripheral neuropathy | 19 (10.4) | 2 (0.9) | < .001 | 3 (4.2) | 0 (0) | .245 |
| Fatigue | 13 (7.1) | 23 (10.1) | .288 | 5 (6.9) | 10 (13.9) | .275 |
| Gastrointestinal toxicity | 12 (6.6) | 14 (6.1) | .863 | 5 (6.9) | 7 (9.7) | .764 |
| Constipation | 9 (4.9) | 0 (0) | .001 | 4 (5.6) | 0 (0) | .120 |
| Diarrhea | 0 (0) | 8 (3.5) | .01 | 0 (0) | 3 (4.2) | .245 |
| Venous thromboembolism | 28 (15.3) | 21 (9.2) | .058 | 14 (19.4) | 8 (11.1) | .165 |
| DVT | 21* (11.5) | 16 (7.0) | .117 | 9* (12.5) | 6 (8.3) | .413 |
| Pulmonary embolism | 7 (3.8) | 5 (2.2) | .385 | 5 (6.9) | 2 (2.8) | .441 |
| Dermatologic | 12 (6.6)† | 21 (9.7)‡ | .258 | 6 (8.3) | 5 (6.9)‡ | > .999 |
| Infections | 15 (8.2) | 30 (13.1) | .109 | 6 (8.3) | 10 (13.8) | .289 |
| Pneumonia | 5 (2.7) | 16 (7.0) | .070 | 1 (1.4) | 8 (11.1) | .033 |
| Sepsis | 2 (1.1) | 4 (1.8) | .696 | 1 (1.4) | 0 (0) | > .999 |
| Cardiovascular | 10 (5.5) | 10 (4.4) | .614 | 5 (6.9) | 5 (6.9) | > .999 |
| Transaminase increase | 0 (0) | 7 (3.1) | .019 | 0 (0) | 4 (5.6) | .120 |
| Myopathy | 4 (2.2) | 1 (0.4) | .177 | 2 (2.8) | 1 (1.4) | > .999 |
| . | All patients . | High-dose dexamethasone patients . | ||||
|---|---|---|---|---|---|---|
| thal/dex (n = 183), n (%) . | len/dex (n = 228), n (%) . | P . | thal/dex (n = 72), n (%) . | len/dex (n = 72), n (%) . | P . | |
| Treatment-related deaths | 1 (0.5) | 3 (1.3) | .632 | 1 (1.4) | 2 (2.8) | > .999 |
| At least one grade 3 or 4 adverse event | 100 (54.6) | 131 (57.5) | .568 | 44 (61.1) | 51 (70.8) | .218 |
| Hematologic | ||||||
| Anemia | 0 (0) | 10 (4.4) | .003 | 0 (0) | 3 (4.2) | .245 |
| Thrombocytopenia | 0 (0) | 11 (4.8) | .002 | 0 (0) | 3 (4.2) | .245 |
| Neutropenia | 1 (0.6) | 32 (14.0) | < .001 | 0 (0) | 10 (13.9) | .001 |
| Extrahematologic | ||||||
| Peripheral neuropathy | 19 (10.4) | 2 (0.9) | < .001 | 3 (4.2) | 0 (0) | .245 |
| Fatigue | 13 (7.1) | 23 (10.1) | .288 | 5 (6.9) | 10 (13.9) | .275 |
| Gastrointestinal toxicity | 12 (6.6) | 14 (6.1) | .863 | 5 (6.9) | 7 (9.7) | .764 |
| Constipation | 9 (4.9) | 0 (0) | .001 | 4 (5.6) | 0 (0) | .120 |
| Diarrhea | 0 (0) | 8 (3.5) | .01 | 0 (0) | 3 (4.2) | .245 |
| Venous thromboembolism | 28 (15.3) | 21 (9.2) | .058 | 14 (19.4) | 8 (11.1) | .165 |
| DVT | 21* (11.5) | 16 (7.0) | .117 | 9* (12.5) | 6 (8.3) | .413 |
| Pulmonary embolism | 7 (3.8) | 5 (2.2) | .385 | 5 (6.9) | 2 (2.8) | .441 |
| Dermatologic | 12 (6.6)† | 21 (9.7)‡ | .258 | 6 (8.3) | 5 (6.9)‡ | > .999 |
| Infections | 15 (8.2) | 30 (13.1) | .109 | 6 (8.3) | 10 (13.8) | .289 |
| Pneumonia | 5 (2.7) | 16 (7.0) | .070 | 1 (1.4) | 8 (11.1) | .033 |
| Sepsis | 2 (1.1) | 4 (1.8) | .696 | 1 (1.4) | 0 (0) | > .999 |
| Cardiovascular | 10 (5.5) | 10 (4.4) | .614 | 5 (6.9) | 5 (6.9) | > .999 |
| Transaminase increase | 0 (0) | 7 (3.1) | .019 | 0 (0) | 4 (5.6) | .120 |
| Myopathy | 4 (2.2) | 1 (0.4) | .177 | 2 (2.8) | 1 (1.4) | > .999 |